ID: ALA346970

Max Phase: Preclinical

Molecular Formula: C18H16N2O2

Molecular Weight: 292.34

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(C)=C1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O

Standard InChI:  InChI=1S/C18H16N2O2/c1-13(2)16-17(21)19(14-9-5-3-6-10-14)20(18(16)22)15-11-7-4-8-12-15/h3-12H,1-2H3

Standard InChI Key:  PDPQOBMGUDTPIR-UHFFFAOYSA-N

Associated Targets(Human)

Cyclooxygenase 1258 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 292.34Molecular Weight (Monoisotopic): 292.1212AlogP: 3.32#Rotatable Bonds: 2
Polar Surface Area: 40.62Molecular Species: HBA: 2HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 3.34CX LogD: 3.34
Aromatic Rings: 2Heavy Atoms: 22QED Weighted: 0.63Np Likeness Score: -0.12

References

1. Vennerstrom JL, Holmes TJ..  (1987)  Preparation and evaluation of electrophilic derivatives of phenylbutazone as inhibitors of prostaglandin-H synthase.,  30  (3): [PMID:3102742] [10.1021/jm00386a020]

Source